PDCD1 and neoplasm: Indeed, pembrolizumab and nivolumab, both of which are anti‐CD279 monoclonal antibodies, have shown promising tumor killing effects and have been approved by the US Food and Drug Administration to treat melanoma and non‐small cell lung cancer clinically.